GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Cyclically Adjusted Book per Share

Intra-Cellular Therapies (STU:23I) Cyclically Adjusted Book per Share : €7.72 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Intra-Cellular Therapies's adjusted book value per share for the three months ended in Mar. 2024 was €5.658. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7.72 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Intra-Cellular Therapies's average Cyclically Adjusted Book Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Intra-Cellular Therapies's current stock price is €62.50. Intra-Cellular Therapies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €7.72. Intra-Cellular Therapies's Cyclically Adjusted PB Ratio of today is 8.10.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intra-Cellular Therapies was 9.14. The lowest was 5.87. And the median was 7.35.


Intra-Cellular Therapies Cyclically Adjusted Book per Share Historical Data

The historical data trend for Intra-Cellular Therapies's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Cyclically Adjusted Book per Share Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 6.97 7.41

Intra-Cellular Therapies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.51 7.24 7.93 7.41 7.72

Competitive Comparison of Intra-Cellular Therapies's Cyclically Adjusted Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Cyclically Adjusted PB Ratio falls into.



Intra-Cellular Therapies Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intra-Cellular Therapies's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.658/131.7762*131.7762
=5.658

Current CPI (Mar. 2024) = 131.7762.

Intra-Cellular Therapies Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.476 100.560 4.555
201409 3.538 100.428 4.642
201412 3.314 99.070 4.408
201503 5.876 99.621 7.773
201506 5.176 100.684 6.774
201509 10.396 100.392 13.646
201512 10.131 99.792 13.378
201603 9.404 100.470 12.334
201606 8.765 101.688 11.358
201609 8.223 101.861 10.638
201612 8.223 101.863 10.638
201703 7.603 102.862 9.740
201706 6.962 103.349 8.877
201709 6.171 104.136 7.809
201712 7.033 104.011 8.910
201803 6.275 105.290 7.854
201806 6.109 106.317 7.572
201809 5.539 106.507 6.853
201812 5.087 105.998 6.324
201903 4.633 107.251 5.692
201906 4.118 108.070 5.021
201909 3.729 108.329 4.536
201912 3.162 108.420 3.843
202003 5.884 108.902 7.120
202006 5.047 108.767 6.115
202009 7.515 109.815 9.018
202012 6.710 109.897 8.046
202103 6.338 111.754 7.474
202106 5.651 114.631 6.496
202109 5.084 115.734 5.789
202112 4.516 117.630 5.059
202203 7.656 121.301 8.317
202206 7.240 125.017 7.631
202209 7.310 125.227 7.692
202212 6.531 125.222 6.873
202303 6.127 127.348 6.340
202306 5.832 128.729 5.970
202309 5.849 129.860 5.935
202312 5.627 129.419 5.729
202403 5.658 131.776 5.658

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Intra-Cellular Therapies  (STU:23I) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Intra-Cellular Therapies's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=62.50/7.72
=8.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Intra-Cellular Therapies was 9.14. The lowest was 5.87. And the median was 7.35.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Intra-Cellular Therapies Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (STU:23I) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (STU:23I) Headlines

No Headlines